Evidence map›Paper›PMID 33649099›Full record

ArticleJournal of the American Society of Nephrology : JASN2021

Authors' Reply.

Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Tadao AkizawaDepartment of Nephrology, Showa University School of Medicine, Tokyo, Japan.
Manabu IwasakiDepartment of Data Science, Yokohama City University, Yokohama, Japan.
Yusuke YamaguchiJapan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan.
Yoshikatsu MajikawaJapan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan.
Michael ReuschDevelopment Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic kidney diseaseerythropoiesis-stimulating agenthemodialysishypoxia-inducible factorrandomized controlled trial

Identifiers

PMID33649099
PMCPMC8017550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.